A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma. A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results